EMEA-000309-PIP07-21-M01 - paediatric investigation plan
tocilizumab
PIPHuman
Key facts
- Invented name
- RoActemra
- Active Substance
- tocilizumab
- Therapeutic area
- Infections and infestations
- Decision number
- P/0028/2024
- PIP number
- EMEA-000309-PIP07-21-M01
- Pharmaceutical form(s)
- Concentrate for solution for infusion
- Condition(s) / indication(s)
- Treatment of Coronavirus disease 2019 (COVID-19)
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Roche Registration GmbH
E-mail: global.eu_regulatory_office@roche.com
Tel: +41 616879411- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date